Multiple myeloma;DAS MULTIPLE MYELOM

Therapeutische Umschau

Volumn 53, Issue 2, 1996, Pages 147-151

  Peest, D ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHOTREXATE; PAMIDRONIC ACID; PREDNISONE; VINCRISTINE;

HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PROGNOSIS; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS;

EID: 0029882505     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Kyle R. A.: Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am. J. Med. 64, 814-826, 1978.
2. Durie B. G. M., Salmon S. E.: A clinical staging system for multiple myeloma. Cancer 36, 842-852, 1975.
3. Peest D., Coldewey R., Deicher H., Sailer M., Vykoupil C., Leo R., Georgii A., Karow J., Hoeppner E., Diehl V., Essers U., Gamm H., Glück S., Görg K., Gramatzki M., Hauswaldt C., Heilmann E., Hiemeyer V., Keyserlingk H. J., Kindler A., Dertel J., Planker M., Reinold H. M., Schäfer E., Schumacher K., Tirier C., Urbanitz D., Suchy B. R., Währisch J.: Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups. Eur. J. Cancer 29A, 978-983, 1993.
4. Gregory W. M., Richards M. A., Malpas J. S.: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol. 10, 334-342, 1992.
5. Peest D., Deicher H., Coldewey R., Leo R., Bartl R., Bartels H., Braun H. J., Fett W., Fischer J. T., Göbel B., Harms P., Henke R., Hoffman L., Klein B., Kreuser E. D., Maier W. D., Meier C. R., Oertel J., Petit M., Planer M., Respondek M., Schäfer E., Schumacher K., Stennes M., Stenzinger W., Tirier C., Wagner H., Weh H. J., von Wussow P., Wysk J.: A comparison of polychemotherapy and melphalan/ prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur. J. Cancer 31A, 146-151, 1995.
6. Alexanian R., Haut A., Khan A. U., Lane M., McKelvey E. M., Migliore P. H., Stuckey W. J., Wilson H. E.: Treatment for multiple myeloma. JAMA 208, 1680-1685, 1969.
7. Lee B. J., Sahakian G., Clarkson B. D., Krakow I. H.: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer 33, 533-538, 1974.
8. Durie B. G. M., Dixon D. O., Carter S., Stephens R., Rivkin S., Bonnet J., Salmon S. E., Dabich L., Files J. C., Costanzi J. J.: Improved survival duration with combination chemotherapy induction for multiple myeloma: a southwest oncology group study. J. Clin. Oncol. 4, 1227-1237, 1986.
9. Barlogie B., Smith L., Alexanian R.: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med. 310, 1353-1356, 1984.
10. Alexanian R., Barlogie B., Dixon D.: High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med. 105, 8-11, 1986.
11. Jagannath S., Barlogie B., Dicke K., Alexanion R., Zagars G., Cheson B., Lemaislre F. C., Smallwood L., Pruitt K., Dixon D. O.: Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 76, 1860-1866, 1990.
12. Attal M., Huguet F., Schlaifer D., Payen C., Laroche M., Fournie B., Mazieres B., Pris J., Laurent G.: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79, 1130-1136, 1992.
13. Gahrton G., Tura S., Ljungman P., Belanger C., Brandt L., Cavo M., Facon T., Granena A., Gore M., Gratwohl A., Löwenberg B., Nikoskelainen J., Reifers J. J., Samson D., Verdonck L., Volin L.: Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N. Engl. J. Med. 325, 1267-1273, 1991.
14. Bergsagel D. E., Alexanian R., Avvisati G., Bataille R., Barlogie B., Borden E., Caligaris-Cappio F., Deicher H., Durie B. G. M., Giles F., Huhn D., Klein B., Kyle R. A., Ludwig H., Mellstedt H., Peest D., Salmon S. E., Westin J., von Wussow P.: Interferons in the treatment of multiple myeloma. J. Clin. Oncol. 8, 1444-1445, 1990.
15. Salmon S. E., Crowley J. J., Grogan T. M., Finley P., Pugh R. P., Barlogie B.: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J. Clin. Oncol. 12, 2405-2414, 1994.
16. Ludwig H., Cohne A. M., Polliack A., Huber H., Nachbaur D., Senn H.-J., Morant R., Eckhardt S., Günczler P., Seewann H. L., Schüller J., Rhyner K., Cavalli F., Fritz E.: Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann. Oncol. 6, 467-476, 1995.
17. Berenson J., Lichtenstein A., Porter L., Bordoni R., George S., Lipton A., Keller A., Heffernan M., Seaman J., Knight R.: Long-term pamidronate disodium therapy leads to a reduction in skeletal related episodes (SREs) in stage III multiple myeloma patients and an improvement in survival in those on salvage therapy (abstract no. 1753). Blood 86 (supp. 1), Abstract. 442a. 1995.